Avvio della tecnologia nello studio sul diabete di tipo 1 a rischio (STAR-T1D)
Avvio della tecnologia nello studio sul diabete di tipo 1 a rischio (STAR-T1D).
Diabetes technology has revolutionized T1D management, disparities in technology access are evident among racial-ethnic minorities, patients with lower socioeconomic status and those with poorly controlled T1D (A1c>8.5%). In order to examine whether diabetes technology can reduce diabetes care burdens and enhance outcomes among some of highest need patients, diabetes technology clinical trials must be expanded beyond the very select populations included in studies thus far (ie., mostly White, higher SES). Therefore, the investigators propose to perform a pilot RCT of hybrid closed-loop insulin pump therapy (HCL) in 40 diverse adult patients with poorly controlled T1D (HbA1c ≥8.0%) from the largest academic and safety net health systems in the Los Angeles region to determine the feasibility of a RCT in this population and identify facilitators and barriers of effective use of closed loop insulin pump therapy in patients with poorly controlled T1D.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Estelle M Everett, MD, MHS
- Numero di telefono: 310-267-0625
- Email: eeverett@mednet.ucla.edu
Luoghi di studio
-
-
California
-
Santa Monica, California, Stati Uniti, 90404
- Reclutamento
- UCLA
-
Contatto:
- Rebecca Lopez, BA
- Numero di telefono: (310) 882-0033
- Email: rebeccalopez@mednet.ucla.edu
-
Contatto:
- Erin E Shaw, B.S.
- Email: EEShaw@mednet.ucla.edu
-
Sylmar, California, Stati Uniti, 91342
- Reclutamento
- Olive View-UCLA Medical Center
-
Contatto:
- Hugo Torres, MD
- Numero di telefono: 747-210-3000
- Email: HATorres@mednet.ucla.edu
-
Torrance, California, Stati Uniti, 90502
- Reclutamento
- Harbor-UCLA Medical Center
-
Contatto:
- Joyce A Graham
- Numero di telefono: (310) 222-1870
- Email: jgraham@lundquist.org
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Type 1 Diabetes
- A1c ≥ 8.0%
- Not insulin pump user
- Primary language of English or Spanish
- Have medical insurance coverage
Exclusion Criteria:
- No measured A1c in the past year
- Have comorbidities that can result in inaccurate hemoglobin A1c
- Have cognitive, physical or mental impairment precluding diabetes technology use
- Limited life expectancy (<1 year)
- Pregnancy
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Ricerca sui servizi sanitari
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Hybrid Closed Loop Insulin Pump System
Participants will meet 1:1 with our CDE for at least 6 sessions over 6 weeks. Sessions will cover self-management basics, carb counting, CGM interpretation, hypoglycemia and hyperglycemia management and troubleshooting device issues. The investigators will follow up with participants in 24 and 72 hours after CGM and insulin pump initiation, respectively, to answer any device related questions that may arise in between sessions. Participants will follow up at intervals of 1-4 weeks throughout the study. During visits, the investigators will assess for adherence and adverse effects and evaluate device and safety issues associated with pump settings in the HCL arm. The investigators will repeat A1c at 12 weeks and 24 weeks and administer follow up questionnaires at 12 and 24 weeks. |
Patients will be started on an automated insulin delivery system. |
|
Nessun intervento: Control
Participants in the control arm will receive diabetes education at a similar frequency as the intervention group. Diabetes education for the control group will be a combination of in-person visits with the CDE and telephone brief diabetes education sessions. Participants will follow up at intervals of 1-4 weeks throughout the study. During visits, the investigators will assess for adherence and adverse effects. The investigators will repeat A1c at 12 weeks and 24 weeks and administer follow up questionnaires at 12 and 24 weeks. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Proportion of screened participants that are eligible
Lasso di tempo: 6 months
|
Eligible among screened, enrolled among eligible, excluded among screened (and why) based on screening, recruitment and enrollment data. |
6 months
|
|
Proportion of enrolled participants that are randomized
Lasso di tempo: 6 months
|
Randomized among enrolled, and receiving allocated intervention among randomized. |
6 months
|
|
Proportion of average time delay to enrollment
Lasso di tempo: 6 months
|
Average time delay from screening to enrollment. |
6 months
|
|
Proportion of retention among participants randomized to the Intervention Group
Lasso di tempo: 6 months
|
Retention among participants receiving allocated intervention after being randomized and discontinued intervention among randomized. |
6 months
|
|
Proportion of retention among participants randomized
Lasso di tempo: 6 months
|
Participants lost to follow-up among those initially randomized. |
6 months
|
|
Proportion of retention among participants randomized
Lasso di tempo: 6 months
|
Retention rates by participants completing all research assessments among randomized. |
6 months
|
|
Number of participants who adhere to assigned treatment
Lasso di tempo: 6 months
|
Treatment-specific adherence, Adherence to study protocol and Proportion of planned assessments that are completed. Fidelity, which pertains to guaranteeing that the intervention is delivered in accordance with the established protocol, will be summarized by study arms, and differences between arms will be examined using t-tests or two-sample tests of proportions as appropriate. Adherence, which relates to the extent to which participants follow the treatment and study protocol, as well as the proportion of planned assessments completed, will be summarized by study arms, and differences between arms will be examined using t-tests or two-sample tests of proportions as appropriate. |
6 months
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in A1c
Lasso di tempo: 6 months
|
Serum Hemoglobin A1c laboratory measurement |
6 months
|
|
Episodes and % of time with severe hypoglycemia ( BG <54 mg/dl)
Lasso di tempo: 6 months
|
Hypoglycemia will be measure by combining CGM metrics and glucometer to report severe hypoglycemia in mg/dl. |
6 months
|
|
Mean Diabetes Ketoacidosis Episodes Incidence
Lasso di tempo: 6 months
|
Assess instances of diabetic ketoacidosis through participant surveys and comprehensive chart reviews. |
6 months
|
|
ED visits/Hospitalizations Number of diabetes related ED visits or hospitalizations
Lasso di tempo: 6 months
|
Number of diabetes related ED visits or hospitalizations |
6 months
|
|
Treatment Burden and Satisfaction: Diabetes Distress
Lasso di tempo: 6 months
|
Assessing treatment burden through the Type 1 Diabetes Distress Assessment System T1DDAS, which comprises eight questions and evaluates ten prevalent sources of diabetes distress in adults with type 1 diabetes. The score indicates the level of diabetes distress reported by the respondent, with higher scores indicating greater intensity. The core scale scoring ranges 1 to 5. This scale assesses each of ten common Sources of diabetes distress for adults with type 1 diabetes: Financial Worries, Interpersonal Challenges, Management Difficulties, Shame, Hypoglycemia Concerns, Healthcare Quality, Lack Of Diabetes Resources, Technology Challenges, Burden To Others, Worries About Complications. The higher the score, the more impactful that Source is likely to be in contributing to diabetes distress for this individual with the minimum value being 1 and maximum value being 5. |
6 months
|
|
Treatment Burden and Satisfaction: Insulin Treatment Satisfaction
Lasso di tempo: 6 months
|
Assessed treatment burden and satisfaction using the Insulin Treatment Satisfaction Questionnaire (ITSQ), consisting of 22 questions among 5 content clusters with a score from 0 to 100% where a higher score indicates greater satisfaction with insulin treatment. The scale explores perceptions of current insulin treatment and its impact on daily life. |
6 months
|
|
Treatment Burden and Satisfaction: Glucose Monitoring System Satisfaction (GMSS)
Lasso di tempo: 6 months
|
Examined treatment burden and satisfaction employing the Glucose Monitoring System Satisfaction Survey (GMSS), comprising 15 questions divided into four subcategories: openness, emotional burden, behavioral burden and trust. Higher scores within each subcategory denote either greater satisfaction or burden, depending on the specific aspect assessed with the minimum value being 1 and maximum value being 5. The total scare has a minimum value of 1 and maximum value of 15 with higher scores indicating greater satisfaction. The scores are obtained by calculating the mean for each. |
6 months
|
|
Treatment Burden and Satisfaction: Motivation and Attitudes Towards Changing Health (MATCH)
Lasso di tempo: 6 months
|
Assessed treatment burden and satisfaction using the Motivation and Attitudes towards Health Scale (MATCH), consisting of nine questions categorized into four subgroups: willingness to make changes, perceived ability to make or maintain changes, feeling changes are worthwhile, and overall mean/average of willingness, able, and worthwhile. Scores are calculated by determining the mean or average response within each category with higher scores meaning a better outcome. WILLINGNESS: minimum value is 1 and maximum value is 5. ABLE: minimum value is 1 and maximum value is 5. WORTHWHILE: minimum value is 1 and maximum value is 5. TOTAL SCALE: minimum value is 1 and maximum value is 9. |
6 months
|
Collaboratori e investigatori
Sponsor
Sponsor
Collaboratori
Collaboratori
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- 22-000236
- 5K23DK132482-02 (Sovvenzione/contratto NIH degli Stati Uniti)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .